Skip Navigation


NDT Advance Access originally published online on January 16, 2009
Nephrology Dialysis Transplantation 2009 24(6):1870-1875; doi:10.1093/ndt/gfn763
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/6/1870    most recent
gfn763v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Escher, G.
Right arrow Articles by Mohaupt, M. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Escher, G.
Right arrow Articles by Mohaupt, M. G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



High aldosterone-to-renin variants of CYP11B2 and pregnancy outcome

Geneviève Escher1, Martino Cristiano1, Maja Causevic1, Marc Baumann2, Felix J. Frey1, Daniel Surbek2 and Markus G. Mohaupt1

1 Department of Nephrology/Hypertension 2 Department of Obstetrics and Gynecology, University of Bern, Berne, Switzerland

Correspondence and offprint requests to: Markus G. Mohaupt; E-mail: markus.mohaupt{at}insel.ch



  Abstract

Background. Increased aldosterone concentrations and volume expansion of normal pregnancies are hallmarks of normal pregnancies and blunted in pre-eclampsia. Accordingly, we hypothesized an active mineralocorticoid system to protect from pre-eclampsia.

Methods. In pregnant women (normotensive n = 44; pre-eclamptic n = 48), blood pressure, urinary tetrahydro-aldosterone excretion and activating polymorphisms (SF-1 site and intron 2) of the aldosterone synthase gene (CYP11B2) were determined; 185 non-pregnant normotensive individuals served as control. Amino acid-changing polymorphisms of the DNA- and agonist-binding regions of the mineralocorticoid receptor were evaluated by RT-PCR, SSCP and sequencing.

Results. Urinary tetrahydro-aldosterone excretion was reduced in pre-eclampsia as compared to normal pregnancy (P < 0.05). It inversely correlated with blood pressure (r = 0.99, P < 0.04). Homozygosity for activating CYP11B2 polymorphisms was preferably present in normotensive as compared to pre-eclamptic pregnancies, identified (intron 2, P = 0.005; SF-1 site, P = 0.016). Two mutant haplotypes decreased the risk of developing pre-eclampsia (RR 0.16; CI 0.05–0.54; P < 0.001). In contrast, intron 2 wild type predisposed to pre-eclampsia (P < 0.0015). No functional mineralocorticoid receptor mutant has been observed.

Conclusions. High aldosterone availability is associated with lower maternal blood pressure. In line with this observation, gain-of-function variants of the CYP11B2 reduce the risk of developing pre-eclampsia. Mutants of the mineralocorticoid receptor cannot explain the frequent syndrome of pre-eclampsia.

Keywords: aldosterone synthase; aldosterone; arterial hypertension; pre-eclampsia; pregnancy outcome

Received for publication: 26. 9.08
Accepted in revised form: 19.12.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
M. D. Lindheimer and P. August
Aldosterone, maternal volume status and healthy pregnancies: a cycle of differing views
Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1712 - 1714.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.